Evotec
Cécile Dumas has had diverse work experience in procurement and logistics roles. Cécile started their career as a Marketing & Publicity Buyer at Société Générale, managing RFQs and recruitment projects. Cécile then moved to Hager Group as an OpEx Buyer, responsible for PPE RFQs. After that, they worked at Veolia Water Technologies as a Project Buyer and Logistics Officer, managing international WWTP projects and logistics contracts. Cécile later became a Global Category Buyer at Veolia, negotiating contracts for filtration equipment and automation systems. Cécile then joined OTV | Veolia Water Technologies as a Project Procurement and Logistics Manager, overseeing the supply chain team for WWTP projects in Eastern Europe. Cécile then spent two years at Dürr as a Procurement, Logistics, and Facility Manager, improving SAP system compliance and achieving cost savings. After a consulting mission at ARCYS, they joined Evotec as the Head of Procurement and Logistics France, and later became the Vice President Head of Purchasing and Logistics France, leading the French supply chain and global commodity management. Cécile'smost recent role is heading the Global Commodity of scientific CapEx and maintenance for Evotec.
Cécile Dumas obtained a Master 2 degree in Supply Chain Management from EM Strasbourg Business School from 2000-2004. Cécile then pursued a Master 2 in International Purchasing from Université Robert Schuman (Strasbourg III) from 2005-2006. Additionally, they completed a Master of Business Administration (MBA) in Supply Chain Management from Universidad de Alcalá in 2002-2003. Prior to that, they prepared for the Concours grandes écoles at lycée saliège from 1998-2000.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.